Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd, and Hong Kong Science & Technology Parks (HKSTP) announced a partnership to promote a biomedicine cultivation program in the HKSTP. No financial details were disclosed.
Program Objectives and Support
The program aims to attract the world’s top biomedical start-ups to settle in Hong Kong and assist them in entering the Guangdong Hong Kong Macao Greater Bay Area and the Yangtze River Delta region led by Shanghai. This initiative will strengthen the construction of scientific research and innovation platforms in both regions and jointly promote the development of China’s biomedical industry. As much as 14,000 square feet of shared workspaces will be established in the park, where partners will enjoy resources and support services provided by Incu-Bio.
Support Services and Investment
In addition to the workspace, Shanghai Pharmaceuticals and the Innovation Center will provide guidance and support services for participating enterprises. These services include laboratory sites and office facilities, professional technology platforms and clinical R&D resources, commercial services, marketing expansion, and more. Both entities are expected to support the companies through capital investment or by cultivating investment into shares.-Fineline Info & Tech
